Fibrinolytic activation markers predict myocardial infarction in the elderly: The cardiovascular health study

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 19, Issue 3, 1999, Pages 493-498

  Cushman, Mary ^a,b   Lemaitre, Rozenn N ^c   Kuller, Lewis H ^d   Psaty, Bruce M ^c   Macy, Elizabeth M ^b   Sharrett, A Richey ^e   Tracy, Russell P ^b  

^a UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF VERMONT   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^e NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

Blood coagulation; Elderly; Fibrinolysis; Myocardial infarction; Risk factors

Indexed keywords

ANTIPLASMIN; C REACTIVE PROTEIN; D DIMER; FIBRINOGEN; PLASMIN; PLASMINOGEN ACTIVATOR INHIBITOR 1;

AGED; ARTERY THROMBOSIS; ARTICLE; CASE CONTROL STUDY; CONTROLLED STUDY; CORONARY RISK; FEMALE; FIBRINOLYSIS; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

EID: 0032974070     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.19.3.493     Document Type: Article

References (33)

1. National Center for Health Statistics. Advance Report of Final Mortality Statistics, 1987: Hyattsville, Md: Public Health Service; 1989.
2. Kuller LH, Shemanski L, Psaty BM, Borhani NO, Gardin J, Haan MN, O'Leary DH, Savage PJ, Tell GS, Tracy R. Subclinical disease as an independent risk factor for cardiovascular disease. Circulation. 1995;92: 720-726.
3. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes (second of two parts). N Engl J Med. 1992;326:310-318.
4. Holvoet P, de Boer A, Verstreken M, Collen D. An enzyme-linked immunosorbent assay (ELISA) for the measurement of plasmin-α-2-antiplasmin complex in human plasma: application to the detection of in vivo activation of the fibrinolytic system. Thromb Haemost. 1986;56: 124-127.
5. Kornelisse RF, Hazelzet JA, Savelkoul HF, Hop WC, Suur MH, Borsboom AN, Risseeuw-Appel IM, van der Voort E, de Groot R. The relationship between plasminogen activator inhibitor-1 and proinflammatory and counterinflammatory mediators in children with meningococcal septic shock. J Infect Dis. 1996;173:1148-1156.
6. Juhan-Vague I, Alessi MC, Vague P. Increased plasma plasminogen activator inhibitor 1 levels: a possible link between insulin resistance and atherothrombosis. Diabetologia. 1991;34:457-462.
7. Ridker PM, Hennekens CH, Cerskus A, Stampfer MJ. Plasma concentration of cross-linked fibrin degradation product (D-dimer) and the risk of future myocardial infarction among apparently healthy men. Circulation. 1994;90:2236-2240.
8. Ridker PM, Vaughan DE, Stampfer MJ, Manson JE, Hennekens CH. Endogenous tissue-type plasminogen activator and risk of myocardial infarction. Lancet. 1993;341:1165-1168.
9. Hamsten A, de Faire U, Walldius G, Dahlen G, Szamosi A, Landou C, Blomback M, Wiman B. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet. 1987;2:3-9.
10. Juhan-Vague I, Pyke SDM, Alessi MC, Jespersen J, Haverkate F, Thompson SG, on behalf of the ECAT Study Group. Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. Circulation. 1996;94:2057-2063.
11. Lowe GDO, Yarnell JWG, Sweetnam PM, Rumley A, Thomas HF, Elwood PC. Fibrin D-dimer, tissue plasminogen activator, plasminogen activator inhibitor, and the risk of major ischemic heart disease in the Caerphilly Study. Thromb Haemost. 1998;79:129-133.
12. Montes R, Pàramo JA, Anglès-Cano E, Rocha A. Development and clinical application of a new ELISA assay to determine plasmin-α-2-antiplasmin complexes in plasma. Br J Haematol. 1996;92:979-985.
13. Tracy RP, Bovill EG. Thrombosis and cardiovascular risk in the elderly. Arch Pathol Lab Med. 1992;116:1307-1312.
14. Fried LP, Borhani NO, Enright P, Furberg CD, Gardin JM, Kronmal RA, Kuller LH, Manolio TA, Mittelmark MB, Newman A, O'Leary DH, Psaty B, Rautaharju P, Tracy RP, Weiler PG, CHS Research Group. The Cardiovascular Health Study: design and rationale. Ann Epidemiol. 1991; 1:263-276.
15. O'Leary DH, Polak JF, Wolfson SK, Bond MG, Bommer W, Sheth S, Psaty BM, Sharrett AR, Manolio TA, for CHS Investigators. Use of sonography to evaluate carotid atherosclerosis in the elderly: the Cardiovascular Health Study. Stroke. 1991;22:1155-1163.
16. Gardin JM, Wong JD, Bommer W, Klopfenstein HS, Smith VE, Tabatznik G, Siscovick D, Lobodzinski S, Anton-Culver H, Manolio TA. Echocardiographic design of a multi-center investigation of free living elderly subjects. J Am Soc Echocardiol. 1992;5:63-72.
17. Furberg CD, Manolio TA, Psaty BM, Bild DE, Borhani NO, Newman A, Tabatznik B, Rautaharju PM, for the Cardiovascular Health Study Research Group. Major electrocardiographic abnormalities in persons aged 65 years and older (the Cardiovascular Health study). Am J Cardiol. 1992;69:1329-1335.
18. Tracy RP, Psaty BM, Macy E, Bovill EG, Cushman M, Cornell ES, Kuller LH. Lifetime smoking exposure affects the association of C-reactive protein with cardiovascular disease risk factors and subclinical disease in healthy elderly subjects. Arterioscler Thromb Vasc Biol. 1997; 17:2167-2176.
19. Ives DG, Fitzpatrick AL, Bild DE, Psaty BM, Kuller LH, Crowley PM, Cruise RG, Theroux S. Surveillance and ascertainment of cardiovascular events: the Cardiovascular Health Study. Ann Epidemiol. 1995;5: 278-285.
20. Tracy RP, Lemaitre RN, Psaty BM, Ives DG, Evans RW, Cushman M, Meilahn EN, Kuller LH. Relationship of C-reactive protein to risk of cardiovascular disease in the elderly: results from the Cardiovascular Health Study and the Rural Health Promotion Project. Arteriosder Thromb Vasc Biol. 1997;17:1121-1127.
21. Cushman M, Cornell ES, Howard PR, Bovill EG, Tracy RP. Laboratory methods and quality assurance in the Cardiovascular Health Study. Clin Chem. 1995;42:264-270.
22. DeClerck PJ, Mombaerts P, Holvoet P, De Mol M, Collen D. Fibrinolytic response and fibrin fragment D-dimer levels in patients with deep vein thrombosis. Thromb Haemost. 1987;58:1024-1029.
23. DeClerck PJ, Alessi MC, Verstreken M, Kruithof EKO, Juhan-Vague I, Collen D. Measurement of plasminogen activator inhibitor 1 (PAI-1) in biological fluids with a murine monoclonal antibody based enzyme-linked immunosorbent assay. Blood. 1988;71:220-225.
24. Macy EM, Meilahn EN, DeClerck PJ, Tracy RP. Sample preparation for plasma measurement of plasminogen activator inhibitor-1 antigen in large population studies. Arch Pathol Lab Med. 1993;117:67-70.
25. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997;336:973-979.
26. Fowkes FGR, Lowe GDO, Housely E, Rattray A, Rumley A, Elton RA, MacGregor IR, Dawes J. Cross-linked fibrin degradation products, progression of peripheral arterial disease, and risk of coronary heart disease. Lancet. 1993;342:84-86.
27. Cortellaro M, Cofrancesco E, Boschetti C, Mussoni L, Donati MB, Cardillo M, Catalano M, Gabrielli L, Lombardi B, Specchia G, Tavazzi L, Tremoli E, Pozzoli E, Turri M, for the PLAT Group. Increased fibrin turnover and high PAI-1 activity as predictors of ischemic events in atherosclerotic patients: a case-control study. Arteriosder Thromb. 1993; 13:1412-1417.
28. Sakkinen PA, Cushman M, Psaty BM, Rodriguez B, Boineau R, Kuller LH, Tracy RP. Relationship of plasmin generation to cardiovascular disease risk factors in elderly men and women. Arterioscler Thromb Vasc Biol. 1999;19:499-504.
29. Calles-Escandon J, Ballor D, Harvey-Berino J, Ades P, Tracy R, Sobel B. Amelioration of the inhibition of fibrinolysis in elderly, obese subjects by moderate energy intake restriction. Am J Clin Nutr. 1996;64:7-11.
30. Cushman M, Cornell ES, Macy EM, Psaty BM, Tracy RP. Correlates of the fibrin fragment D-dimer, a measure of fibrinolysis, in an elderly cohort free of prevalent cardiovascular disease. Circulation. 1995; 92(suppl I):I-624. Abstract.
31. Kuller L, Borhani N, Furberg K, Gardin J, Manolio T, O'Leary D, Psaty B, Robbins J. Prevalence of subclinical atherosclerosis and cardiovascular disease and association with risk factors in the Cardiovascular Health Study. Am J Epidemiol. 1994;139:1164-1179.
32. Sakkinen PA, Macy EM, Callas PW, Cornell ES, Hayes TE, Kuller LH, Tracy RP. Analytical and biological variability in measures of hemostasis, fibrinolysis, and inflammation: assessment and implications for epidemiology. Am J Epidemiol. In press.
33. The Medical Research Council's General Practice Research Framework. Thrombosis prevention trial: randomised trial of low-intensity oral anti-coagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. Lancet. 1998;351:233-241.